Treatment Recommendations for Gastrointestinal Cancers Via Large Language Models

ConditionGastrointestinal Neoplasm Malignant

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorChinese Academy of Sciences

About this trial

This study will evaluate the utility of ChatGPT in recommending treatment plans for patients with gastrointestinal cancers, using both retrospective and prospective data.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥18 years, both male and female.

Pathologically confirmed diagnosis of gastrointestinal cancer (gastric cancer or colorectal Cancer).

Detailed medical records available prior to treatment (including chief complaint, history of present illness, radiological examinations, pathological examinations, laboratory tests, etc.).

Participants will receive complete treatment in the participating hospitals.

Disqualifiers

Participants with cancers other than gastrointestinal cancers.

Participants who receive treatment in multiple hospitals.

Trial design

Design model

Parallel

Treatments tested in this trial

Clinician-Directed Treatment Plan
Other intervention
In this approach, clinicians do not employ any technological assistance and rely solely on their professional expertise and experience to formulate treatment plans for participants.
ChatGPT-Assisted Treatment Plan
Other intervention
In this approach, clinicians utilize the ChatGPT technological tool, formulating treatment plans for participants based on its suggestions and their own professional expertise.

Treatment groups

400 Participants

are divided into 2 treatment groups

Group A: Control groupActive comparator 1 intervention

Group B: GPT-Assisted GroupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Influence Rate of ChatGPT on Treatment Plans

The percentage of the initial 100 participants and the overall participants in the ChatGPT-Assisted group whose treatment plans are adjusted by clinicians after consulting with ChatGPT.

Time frame

Within 24 hours after the treatment plan is determined from the onset of study participation.

Secondary outcomes

3-year Progression-Free Survival (PFS) Rate

Percentage of participants without disease progression over a period of 3 years from the start of treatment.

Time frame

3 years

Other outcomes

5-year Overall Survival (OS) Rate

Percentage of participants who are still alive over a period of 5 years from the start of treatment.

Time frame

5 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Chinese Academy of Sciences

Lead sponsor

ZhuHai Hospital

Collaborator

Fifth Affiliated Hospital, Sun Yat-Sen University

Collaborator

Jiangmen Central Hospital

Collaborator

Peking University Cancer Hospital (Inner Mongolia Campus)

Collaborator

San Raffaele University Hospital, Italy

Collaborator

University Hospital Magdeburg, Germany

Collaborator

City of Hope Medical Center

Collaborator

Source ClinicalTrials.gov

Apply now